• Users Online: 228
  • Print this page
  • Email this page
Ahead of Print

Naltrexone beyond psychiatric domain

 Department of Internal Medicine, BLK-Max Super Speciality Hospital, New Delhi, India

Correspondence Address:
Vivek Pal Singh,
Department of Internal Medicine, BLK-Max Super Speciality Hospital, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injms.injms_35_22

Naltrexone, an opioid receptor (OR) antagonist, at its standard doses, is a United States Federal Drug Administration-approved drug for opioid and alcohol use disorders. However, with the discovery of nonneuropsychiatric effects of OR signaling with low-dose naltrexone, it has found novel applications in inflammatory, malignant, insulin sensitivity-related, and chronic pain conditions. Lower doses also ameliorate its adverse effects. Its off-label use in the abovementioned situations has proven to be cost-effective against costly immunomodulating and antineoplastic drugs. Its lower cost and miniscule margin of interest have precluded in-depth analysis by the pharmaceutical industry. So far, only animal studies, cell culture studies, and case reports have been conducted, some of which exhibit promising benefits. There is a dearth of much-needed quality trials.

Print this article
  Search Pubmed for
    -  Garg A
    -  Thapliyal K
    -  Singh VP
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded2    

Recommend this journal